| 5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BHB810 for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Breast Radiotherapy for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib + NIVOLUMAB for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carbon ion irradiation for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Community Treatment for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + Gem/Cis for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELI-002 2P for cholangiocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide + Mevrometostat for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FAPi-46 GA-68 for carcinoma, signet ring cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Farletuzumab ecteribulin for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GALLIUM GA-68 GOZETOTIDE for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Haic+tae + tislelizumab + surufatinib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lenvatinib + farletuzumab ecteribulin for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Metformin for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mitomycin for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxcel Q3W for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PD-1antibody plus GEMOX for klatskin tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prostate Radiotherapy + Radical Prostatectomy for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pulmonary segmentectomy for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Segmentectomy for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selpercatinib for carcinoma, medullary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sequential cytoreductive intervention for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SOC plus trastuzumab and pembrolizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonesitatug Vedotin for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonesitatug Vedotin + Rilvegostomig for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sotorasib for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + Bemarituzumab for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + DEPATUXIZUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + NIVOLUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + RAMUCIRUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + TRASTUZUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tamoxifen for carcinoma, intraductal, noninfiltrating | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tarlatamab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Tislelizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| vitamin D 25(OH)D for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for carcinoma, adenoid cystic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cystic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for adenocarcinoma, clear cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zolbetuximab for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|